Our Tiny R&D penny stock company Ceapro is out with Q3 earnings this morning. At a QUICK look:
Definitely looks good. Seems like we are back to the point where the legacy products are allowing cash to build and maybe almost justifies the share price. The R&D efforts could pay off big but and are not adding much to the share price. A couple of concerns. They resumed their beta glucan trial. I was not aware that they had revealed they suspended it though I did notice it was hardly mentioned if at all last quarter. It remains risky but I like having some investment in this. I think I will buy a little more today.